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By E. Vellenga, C A . Uyl-de Groot, R. de W it, H J . Keizer, B. Löwenberg, M .A . fen Haaft, Th J .M . de W itte,
C.A.H. Verhagen, G.J. Stoter, F.F.H, Rutten, N.H. Muider, W .M . Smid, and E.G.E. de Vries
Purpose: To determine whether granulocyte-macro­
phage colony-stimulating factor (GM-CSF) used in addi­
tion to standard inpatient antibiotic therapy shortens the 
period of hospitalization due to chemotherapy-induced 
neutropenic fever.
Patients and Methods: One hundred thirty-four pa­
tients with aliematologic (n = 47) or solid tumor (n = 
87) who had severe neutropenia {< 0.5 x 109/L) and 
fever (>  38.5°C once or >  38°C twice over a 12-hour 
observation period) were randomly assigned to receive 
GM-CSF 5 /ug/kg/d (n = 65) or placebo (n — 69) in con­
junction with broad-spectrum antibiotics for a minimum 
of 4 days and a maximum of 14 days* GM-CSF/placebo 
and antibiotics were stopped if the neutrophil count was 
greater than 1.0 x 109/L and temperature less than 
37.5°C during 2 consecutive days, or for a leukocyte 
count > 1 0 x 1 09/lv both followed by a 24-hour observa­
tion period (hospitalization period).
Results: Compared with placebo, GM-CSF enhanced 
neutrophil recovery. Median neutrophil counts at day 4 
were 2.5 x 109/L (range, 0 to 25) in the GM-CSF arm
and 1.3 x 109/L (range, 0  to 9) in the placebo arm (P <  
.001). No significant difference was observed with re­
gard to median number of days with less than 1.0 x 109/  
L neutrophils (4 v4) or days of fever {3 v3) .  The median 
number of days patients were hospitalized while on 
study was comparable in the GM-CSF and placebo 
groups at 6 (range, 3 to 14) versus 7  (range/ 4  to 14), 
respectively, according to an intention-to-treat analysis 
(P = .27). Quality-of-life scores in 90 patients demon­
strated significant differences in favor of the placebo 
group. Hospital costs were significantly higher for GM- 
CSF -treated patients if GM-CSF was included in the price 
(median costs, $4 ,140 [US] for GM-CSF v $590 for pla­
cebo; P <  .05).
Conclusion: These results indicate that GM-CSF does 
not affect the number of days for resolution of fever or 
the hospitalization period for this patient group, a l­
though a significant effect of GM-CSF was observed on 
neutrophil recovery.
J Clin Oncol 14:619*627, © 1 996 by American So­
ciety of Clinical Oncology.
CHEMOTHERAPY-RELATED neutropenia and fe­ver is a complication that occurs frequently during 
treatment of cancer patients. In particular, the severity 
and duration of neutropenia determines the risk of infec­
tion and the outcome of the patient.1,2 Recently, different 
hematopoietic growth factors (HGFs) have been pro­
duced, which allows the opportunity to modulate the pe­
riod of granulocytopenia.
Two options are available for applying HGFs after 
standard chemotherapy.3 First, HGF can be given as an 
adjunct to chemotherapy until recovery o f peripheral- 
blood counts is noted, in a number of studies, this 
policy has resulted in a 50% reduction of infectious 
complications,4,5 while in other studies, no significant 
effect has been shown with regard to the incidence of 
bacteremia, days o f fever, or hospitalization duration.ü,; 
A second possibility would be to apply HGF only in 
the case of infection.8“n This approach would reduce 
the number of patients exposed to growth factor and 
could potentially restrict the costs o f treatment. A lim ­
ited n u m b er  of studies have tested this approach. Riiko- 
nen et ai9 demonstrated in a randomized study o f 58 
children that the application of granulocyte-macro­
phage colony-stimulating factor (GM-CSF) during fe­
ver and neutropenia resulted in a faster recovery o f the
granulocytic lineage and a shortened period o f hospital­
ization. A  recent double-blind study with granulocyte 
colony-stim ulating factor (G-CSF) in febrile neutro­
penia demonstrated that the greatest benefit was ob­
tained in patients with a documented infection who had 
a neutrophil count less than 0.1 X 109/L at the start o f  
G-CSF administration,10
We describe a prospective multicenter clinical trial de­
signed to compare the effects o f GM-CSF versus placebo 
in 153 adult patients with chemotherapy-related febrile 
neutropenia. The study focused on whether GM-CSF af­
fects the duration o f hospitalization in conjunction with 
quality-of-life and cost-effectiveness analyses.
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PATIENTS A N D  METHODS
Study Population
This study was performed at the Departments of Hematology and/ 
or Oncology of six university hospitals and the Rotterdam Cancer 
Institute from September 1991 to September 1994. Eligible patients 
with chemotherapy-related neutropenia ( <  0.5 X iO'VL) and fever 
(temperature of >  3B°C over a 12-hour observation period or >  
38.5°C once) were entered.
Patients with severe heart, lung, and liver impairment of World 
Health Organization (WHO) grade 3 to 4  were excluded, as were 
patients with acute myeloid leukemia, myelodysplasia, or autologous 
or allogeneic bone marrow transplantation and those patients already 
receiving antibiotics for the suspected infection.
The . tudy protocol was approved by the medical ethical commit­
tees o f  f ie  different hospitals and all patients gave informed consent.
Design incl Treatment
This wi.s a double-blind randomized phase HI study. Patients were 
stratified lor solid or hematologic tumors and for hospital attended. 
Enrolled patients were admitted to the hospital and a full medical 
history was taken and physical examination performed. Baseline 
investigations included full blood cell counts with differential WBC 
counts, and sinus and chest radiographs. Cultures o f  blood (in dupli­
cate), urine, and other suspicious sites were collected. In addition, 
serum was collected and frozen (—80°C) on days 0 and 1 for cytokine 
analysis. GM-CSF (5 /Jg/kg/d) or placebo was administered once 
daily subcutaneously for a minimum o f 4  days and a maximum 
o f 14 days. GM-CSF or placebo was started simultaneously with 
intravenous empiric antibiotics according to standardized local hos­
pital policy. Both antibiotics and GM-CSF/placebo were discon­
tinued if both the lemperalure normalized ( <  37.5°C) and the granu­
locyte count was ^  1.0 X 10*7L for 2 consecutive days. However, 
in the case o f  a leukocyte count s  10 X 10l,/L, application of 
GM-CSF/placebo was stopped while the antibiotic treatment was 
continued until the temperature was normalized for 2 consecutive 
days. The patient was then observed for 24 hours, and if no sign of 
infection was noted, the patient was discharged from the hospital 
and monitored twice weekly for a period of 2 weeks or until the 
next chemotherapy course.
Lyophilized Escherichia cali GM-CSF (Leucomax; Sandoz 
Pharma, Basel, Switzerland/Schering-Plough, Kenilworth, NJ) in 
vials of 400 fj.g protein per vial was reconstituted in 1 mL of water. 
A vial identical in appearance to the active drug but containing 
lyophilized placebo was also provided by Sandoz and used in a 
similar fashion.
Study End Points
The primary end point was hospitalization time with GM-CSF or 
placebo, which comprises the period of resolution of neutropenia 
(>  1.0 x  10tJ/L) and fever defined as a temperature less than 37.5°C 
for 2 consecutive days followed by a 24-hour observation period. 
For this reason, blood and differential counts were performed daily 
and temperature was recorded three times daily. Secondary end 
points were days on antibiotics and incidence of change in antibiotic 
treatment. Inpatients were allowed to enter the study. Some patients 
remained in the hospital after study completion for reasons other 
than continued morbidity related to fever and neutropenia. In these 
cases, the hospitalization duration was the study duration.
Quality - of-Life A n a lys i s
The quality of life of patients was scored by means of written 
questionnaires that were filled in by the patients 1 day after GM-CSF 
or placebo treatment was stopped. Based on methodologie criteria 
concerning cost-effectiveness studies in cancer trials, the patient 
questionnaire consisted of a generic health status measurement in­
strument, a cancer-specific instrument, and a valuation instru­
ment.12,1'1 The Karnofsky performance index and the Nottingham 
Health Profile were included as generic instruments, the Rotterdam 
Symptom Checklist as a cancer-specific instrument, and the EuroQoI 
as a valuation in s t r u m e n t ,T h e  Nottingham Health Profile incor­
porates the dimensions of mobility, emotional reactions, energy, 
social isolation, pain, and sleep. For the general population, the 
average score for all dimensions is less than 10.17 The EuroQoI 
consisted of a descriptive part and a valuation part (a rating scale). 
The descriptive part allows the calculation of utilities. The utility 
scores are based on the validation for each health state o f  patients 
and of a representative panel of the population.10 The average Euro­
QoI score for the general population is greater than 90.17 The Rotter­
dam Symptom Checklist has the potential to add illness or treatment- 
related items. In this study, questions were added on possible side 
effects associated with GM-CSF, namely, constipation, painful 
joints, palpitation rash/eczema, and sweating/perspiring.
Furthermore, data forms were used to obtain daily information on 
patients' quality of life during the period of fever and neutropenia. 
These forms were filled in daily by nurses. The descriptive part of 
the EuroQoI was used, which allowed calculation of utilities.
Cost Analysisw
Cost analysis was based on a detailed review of all activities 
concerning the treatment of patients with fever and leukopenia. 
These activities included days in hospital, consultations, laboratory 
services, diagnostics including imaging procedures, antibiotics, and 
GM-CSF. The data were derived from all registry forms and from 
daily data forms. The latter included information on type of hospital 
ward and consultations.
For each of these cost data, unit prices were determined that 
reflected the real use of resources. The year of study was 1992 ($1 
US «  1.8 Dutch guilders). Patients stayed on wards for regular 
oncologic care, regular hematologic care, protected environment, 
and intensive care. The costs of hospital days were split into direct 
and indirect costs. Direct costs concerned manpower (doctors, 
nurses, etc) and materials (medical devices, supportive patient care, 
etc), indirect costs were related to overhead, The cost of hospitaliza­
tion amounted to approximately $290 (US) per day for regular onco­
logic care, $350 per day for regular hematologic care, $536 for 
staying in a protected environment, and $1,223 for intensive care.
The output of hospital laboratories in the Netherlands is measured 
in terms of a point system. A unit price is associated per point. The 
unit prices differ across types of laboratories. The unit prices per 
point varied from $0.62 (biochemistry and hematology laboratories) 
to $2.81 (virology tests). A routine test (including hemoglobin, leu­
kocytes, and platelets) amounted to 5.75 points and cost $3.58. For 
diagnostics, the Dutch tariff system has been used as an approxima­
tion of unit costs. The drug prices used were wholesale prices. A 
300-jug vial GM-CSF cost $138 and a 400-/¿g vial, $184.
Measurement o f  Serum Cytokine Levels
GM-CSF, G-CSF, interleukin-6 (1L-6), and tumor necrosis factor- 
a  (TNF-a) serum levels were quantified using a human GM-CSF,
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G-CSF, IL-6, oi’ TNF-or enzyme-linked immunosorbent assay
(ELISA) kit (R&D, Cambridge, United Kingdom) as recommended 
by the manufacturer.
Statistical Analysis
The generalized Wilcoxon test was chosen to test the difference 
in duration of hospitalization between the two treatment groups. The 
estimated sample size was based on the H0 hypothesis that the me­
dian duration of hospitalization is 11 days in both Lreatment groups 
versus the H t hypothesis that assumes a clinically relevant difference 
between the two treatment groups of 2 days. Using a significance 
level of .05, a sample size of 70 patients per group showed a power 
calculation of at least 75%,
For comparison of clinical characteristics, a x 2, two-tailed Fisher’s 
exact test, Wilcoxon-Mann-Whitney test, or Student’s t test as appro­
priate was used, It was a feature of the study to allow patients to 
enter more than once. This was the case in 11 patients (GM-CSF v 
four placebo). All patients who fulfilled the entry criteria and re­
ceived at least one dose of study medication were included in the 
intention-to-treat analysis. In the case of premature discontinuation, 
death, or major protocol violation for the main end point analysis, 
the patient was right-censored at day 14. Censoring in this way is 
a worst case scenario in which these patients are regarded as a failure 
to respond to therapy during the whole study period. Cumulative 
rates for the days on study, days of neutropenia, and days of fever 
were estimated by Kaplan-Meier methods. Groups were compared 
by the generalized Wilcoxon test. Data are reported as median sur­
vival and absolute ranges. An additional per-protocol analysis was 
performed using the same approach, with the exception that in the 
case of a noninformative dropout, the patient was censored at the 
time of discontinuation.
The risk reduction for assigned study medication with the theoretic 
discharge from hospital as the dependent variable was adjusted for 
influential baseline covariates, chosen by stepwise selection, by using 
a Cox proportional regression model. The covariates selected were 
more than 11 days after last chemotherapy, solid tumor, and fever 
of unknown origin (FUO),
Only variables whose coefficients had P values less than .05 were 
included. Adjusted risk reductions are presented,
A two-sided probability level of ^  .05 was considered to indicate 
statistical significance. All analysis were performed using Statistical 
Analysis System version 6.08 (SAS Institute, Cary, NC). Quality- 
of-life items are presented as mean scores. For comparison between 
items, Mann-Whitney and x 2 tests were used. The cost of both 
groups was compared with the Mann-Whitney test18
RESULTS
One hundred fifty-three patients were entered onto the 
study (Table 1). Of these, 74 patients received GM-CSF 
and 79 placebo. Nine patients in the GM-CSF group and 
10 in the placebo group were excluded from analysis due 
to ineligibility of main entry criteria, eg, temperature less 
than 38°C or granulocyte count greater than 0.5 X 1091 
L. Subsequently, 134 patients were analyzed according 
to intention-to-treat analysis. Eleven patients (five GM- 
CSF and six placebo) were withdrawn before study com­
pletion and were excluded from the per-protocol analysis. 
Reasons for excluding these patients were as follows:
Table 1. Patient Inclusion
No. of Patients
Variable Tota 1 GM-CSF Placebo
Patients randomized 153 74 79
Ineligibility o f entry criteria 19 9 10
Patients available for intention-to-treat
analysis 134 65 69
Withdrawals before end o f follow-up U
Incorrect treatment on study 2 3
medication or concomitant
medication
Possibility of side effects 1 2
Withdrawal consent 1 1
Adverse event 1 0
Patients available for per-protocol
analysis 123 60 63
incorrect treatment with study medication or concomitant
medication (n =  5), adverse event (n =  1), suspected
side effects o f treatment (n =- 3), and refusal of further
treatment (n — 2).
The baseline characteristics o f the 134 patients are
listed in Table 2. The two treatment groups were well
matched with regard to age, sex, tumor type, and neutro­
phil count. Preceding chemotherapy in the GM-CSF
Table 2. Baseline Characteristics o f Study Patients
GM-CSF Group Placebo Group
(n -  65) (n = 69)
Characteristic No. % No. %
Age, years
Median 49 48
Range 19-73 16-70
Male sex 32 49 36 52
Tumor type
Solid 41 63 46 66
Lymphoma 18 27 21 30
Acute lymphoblastic leukemia 6 9 2 3
Days since last chemotherapy 12 13
Baseline leukocyte count
(X lOVL}
<  0.1 42 64 39 56
0.1 -0.5 23 35 30 43
Baseline neutrophil count
(X 109/  L)
<  0.1 42 64 39 56
0.1-0.5 16 24 21 30
FUO 20 30 27 39
Microbiologically or clinical
documented infection 45 69 42 61
Culture-positive with 
bacteremia 
Culture-positive without 
bacteremia 
Culture-negative but clinically 
documented
12 18 13 18
24 36 19 27
13 10 14
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Fig 1. (A) Neutrophil recovery, (B) temperature curve, and (C) 
number of patients during treatment with GM-CSF or placebo.
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group consisted of a cisplatin-containing (21%), anthracy- 
cline-containing (66%), or high-dose cytarabine-con- 
taining (10%) regimen. In the placebo group, comparable 
treatment schedules were applied: 27% cisplatin-con­
taining, 57% anthracycline-containing, and 2% high-dose 
cytarabilie-containing regimen.
With regard to microbiologic ally or clinically docu­
mented infections, no significant difference was observed 
for bacteremia and culture-positive infections. In addition, 
no significant difference was observed with regard to the 
incidence of FUO, Positive blood cultures consisted of 
44% gram-positive bacteria and 56% gram-negative bac­
teria in the GM-CSF group. In the placebo group, 50% 
of the cultures contained gram-positive and 50% gram- 
negative bacteria.
Neutropenia and Fever
GM-CSF enhanced neutrophil recovery as depicted in 
Fig 1. A significant difference in absolute neutrophil 
counts was observed on days 4 and 5 (P <  .001). A 
difference was also observed for the numbers of mono­
cytes and eosinophils on the last day of GM-CSF/placebo 
treatment in 100 assessable patients. In the GM-CSF 
group, the median number of monocytes was 0.8 X 109/ 
L (range, 0 to 0.4) and of eosinophils 0.5 X 109/L (range, 
0 to 1.2). In the placebo group, these values were 1.2 X 
1.09/L (range, 0.1 to 4.9; P <  .03) and 0.3 X 109/L (range, 
0.0 to 0.5, P =  .45), respectively. However, despite the 
enhancing effect of GM-CSF on neutrophil recovery, no 
differences were observed in the median days of neutro­
phils less than 0.5 X 109/L and 1.0 X 109/L (Table 3).
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Table 3. Days of Neutropenia and Fever and Days on Study 
(hospitalization) per Treatment Group {N -  134}
GM-CSF Piacebo
Variable Median Range Median Range P
ANC <  0.5 X 109/L (days) 3 1-Ì4 4 1-14 NS
ANC <  1.0 X 109/L (days) 4 1-14 4 1-14 NS
ANC at day 4 (X  10VLJ 2.9 0-25 1.3 0-9 <  .005
Fever (days) 3 1-14 3 1 -14 N5
Days of hospitalization 6 3-14 7 4-14 NS
Abbreviations: ANC, absolute neutrophile count; NS, not significant.
No difference was observed in time to resolution of fever. 
The median temperature curve was higher in the GM- 
CSF group compared with the placebo group during the 
first 6 days of treatment, with a significant difference on 
day 2 (P <  .05, Fig 1).
The estimated median survival for the primary end 
point of the study (Fig 2), eg, normalization of tempera­
ture and a granulocyte count greater than 1.0 X 109/L 
during 48 hours or a leukocyte count >  10 X 109/L both
followed by a 24-hour observation period, was reached 
after a median of 6 days (range, 3 to 14) in the GM-CSF 
group and 7 days (range, 4 to 14) in the placebo group 
(P = .27) according to the intention-to-treat analysis. 
Comparable results were obtained with the per-protocol 
analysis: GM-CSF—-6 days (range, 3 to 14); placebo 
6 days (range, 4 to 14) (P = .33). Finally, the proportion 
of patients in the GM-CSF and placebo arms was similar 
with regard to hospitalization period of more than 10 
days: 9% in the GM-CSF group and 10% in the placebo 
group.
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Fig 2. Estimated median survival for the primary end point of the 
study. Wilcoxon, P — .27; log-rank, P — .18.
Antibiotics and GM-CSF
All patients were treated with intravenous antibiotics. 
In the GM-CSF group, 15% received imipenem, 23% 
cefuroxime in combination with an aminoglycoside, 13% 
augmentin in combination with an aminoglycoside, and 
20% ceftazidime. In the placebo group, the percentages 
were, respectively, 11%, 14%, 23%, and 18%. Antibiotic 
treatment was changed in 29% of the GM-CSF group and 
24% of the placebo group. Six patients (9%) treated with 
GM-CSF and three patients (4%) who received placebo 
were given intravenous antifungal therapy. The median 
duration of GM-CSF and placebo application for the total 
group of patients was 5 days in both the GM-CSF arm 
(range, 1 to 14) and placebo arm (range, 1 to 13). How­
ever, antibiotic treatment was not stopped at the same 
day of GM-CSF/placebo discontinuation in all cases. In 
the GM-CSF arm, 16 patients had a prolonged administra­
tion of antibiotic treatment between 3 and 5 days, and 
three patients between 5 and 10 days. In the placebo arm, 
prolonged antibiotic administration was given in eight 
patients between 3 to 5 days and two patients between 7 
to 9 days.
Subgroup and Adjusted and Multivariate Analysis
First, it was evaluated whether a difference in response 
was noted in patients with baseline neutrophil counts less 
than 0.1 X  109/L versus 0.1 to 0.5 X  109/L. No difference 
was observed between both groups for time to reach a 
neutrophil count greater than 1.0 X  109/L in combination 
with time for resolution o f fever. Second, Table 4 lists 
the results o f a Cox proportional hazards regression analy­
sis for the primary end point in which the difference 
between the two treatment regimens was estimated after 
adjustment for the independent associated covariates: 
more than 11 days since last chemotherapy, solid tumor, 
and FUO, GM-CSF application did not influence the pri­
mary end point significantly, but a trend was observed. 
When all prognostic factors were taken into account si­
multaneously in the Cox regression model, the risk reduc­
tion o f the primary end point due to GM-CSF treatment 
was 29% (P = .12). The unadjusted risk reduction of 
GM-CSF treatment was 23% (P = .20).
Table 4. Analysis of Risk of Hospitalization in a Cox Regression Model
Analysis
Risk Réduction 
(%) P
Unadjusted, GM-CSF treatment 
Multivariate {Cox regression model)
23 .20
Days since last chemotherapy ( < 1 1  days} 41 .016
Solid tumor 55 .001
FUO 42 .010
Adjusted, GM-CSF treatment 29 .12
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Supportive Care
The median number of RBC transfusions was identical 
in the GM-CSF group versus the placebo group at two 
(range, zero to eight) (P = .50). The number of platelet 
transfusions given was a median of zero (range, zero to 
five) in the GM-CSF group and zero (range, zero to four) 
in the placebo group {P =  .72).
Results o f Quality-of-Life Analysis
4
The results of the quality-of-life analysis are based on 
113 daily data forms and 90 quality-of-life questionnaires. 
The discrepancy between the numbers of questionnaires 
and data forms is due to a later start of the cost-effective­
ness study. The data forms that are not included are cen­
ter-related, so it is unlikely that as a consequence of this 
a bias would have been introduced. The results of the 
patient questionnaires are listed in Table 5. The scores of 
the Karnofsky performance index were greater among the 
placebo group, ie, a mean value of 63 in the GM-CSF 
group versus 73 in the placebo group (P <  .05). Patients 
in the placebo group reported less complaints than pa­
tients who received GM-CSF treatment. Mobility, emo­
tional, and energy problems were less pronounced in the 
placebo than GM-CSF group (P <  .05). No significant 
differences were noticed in the EuroQol scores using pa-
Table 5, Mean Quality-of-life Scores in Both Treatment Arms
Variable
GM-CSF 
Group 
fn = 46}
Placebo 
Group 
(n = 44) P
Karnofsky index* 63 73 .034
Nottingham Health Profile!
Mobility 30 16 .009
Emotional reactions 20 9 .008
Energy 57 36 .014
Social isolation n 5 .128
Pain 23 19 .151
Sleep 35 24 .116
EuroQol*
Patient score 55 57 .700
Population scoref 54 66 .025
Most important symptoms/complaints§
Fatigue 2.9 2.5 .108
Lack of appetite 2.7 2.0 .006
Lack of energy 2.5 1.9 .003
Dry mouth 2.4 1.9 .161
Sweating, perspiring 2.2 1.9 .555
Sore mouth/pain when swallowing 2.1 2.0 .776
*Range, 0 to 100: From worst (0) to best health states (100). 
iRange, 100 to 0: from worst (100) to best health states (0).
^Utility scores based on valuations of patients and of a representative 
panel of the population for each health state were used to calculate average 
summary scores for each arm.
§Answer possibilities: 1 =  not at all, 2 = a little, 3 =  quite a bit, and 4 
= very much. Average values are presented.
tients values. The population value was in favor of the 
placebo group, namely, 54 in the GM-CSF arm and 66 
in the placebo arm (P <  .05).
The most important complaints and symptoms reported 
on the Rotterdam Symptom Checklist were tiredness, lack 
of appetite, lack of energy, dry mouth, sweating/perspir­
ing, and sore mouth and/or pain when swallowing. Pa­
tients in the placebo group experienced less problems 
concerning appetite and energy than patients in the GM- 
CSF group (P <  .01). Regarding tiredness, dry mouth, 
and sweating, no difference was observed.
The results of the population scores (data forms) de­
rived from the descriptive part of the EuroQol are pre­
sented in Fig 3. Patients who received placebo treatment 
felt better during the hospitalization period than patients 
in the GM-CSF group. From day 8, the observations are 
biased, as many patients had already been discharged 
from the hospital.
Results of Cost Analysis
The median number of days in the hospital in the GM- 
CSF group was 6. Hospital care was classified as follows: 
87% regular oncologic or hematologic care, 11% pro­
tected environment care, and 2% intensive care, Patients 
treated with placebo had a median hospital stay of 7 days. 
This group was divided into 86% regular oncologic or 
hematologic care, 13% care in a protected environment, 
and 1 % intensive care.
The median cost of hospitalization in the GM-CSF 
group was $2,130 (range, $860 to $6,420) and in the 
placebo group $2,450 (range, $1,140 to $7,130). The me­
dian cost of antibiotics amounted to $630 (range, $130 
to $3,790) in the GM-CSF group and to $580 (range, 
$144 to $2,930) in the placebo group. The cost of GM- 
CSF was $ 1,100 (range, $280 to $3,860). Additional costs 
included laboratory services, medical procedures, consul­
tations, and blood transfusions. The median costs were 
equal in both arms and amounted to $470 in the GM- 
CSF group (range, $120 to $2,830) and in the placebo 
group (range, $170 to $2,680), The median of all costs 
was $4,140 (range, $1,710 to $14,650) in the GM-CSF 
group and $3,590 (range, $1,680 to $10,990) in the pla­
cebo group (P <  .05).
Adverse Events
Events observed during the treatment period are listed 
in Table 6. A great variety in events was observed. Myal­
gia and/or rash and/or bone pain and/or edema were noted 
in 20% of GM-CSF-treated patients and 6% of placebo- 
treated patients (not significant). No difference was ob­
served in the mortality rate between both groups. In the
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Fig 3. EuroQol population scores in GM-CSF n = 55) and 
placebo (-0 - , n = 58) groups.
GM-CSF arm, one patient died of acute respiratory dis­
tress syndrome. In the placebo arm, two patients died of 
pulmonary embolism.
Cytokine A nalyses
Serum cytokine levels were measured at presentation 
and 24 hours after initiation of therapy in 60 patients (28 
GM-CSF-treated and 32 placebo-treated, Table 7): eight 
patients with bacteremia, 25 with a clinically documented 
infection, and 27 with FUO. At presentation, high levels 
of IL-6 and G-CSF were observed, especially in patients 
with bacteremia. During the first 24 hours of treatment, 
no change in the cytokine profile was observed due to the 
administration of GM-CSF, although significantly higher 
levels of GM-CSF were measured in the GM -CSF- 
treated group (Table 7).
DISCUSSION
The present study demonstrates that GM-CSF acceler­
ates neutrophil recovery in patients who receive antibiot­
ics for febrile neutropenia after chemotherapy. Enhance­
ment of neutrophil recovery by GM-CSF was irrespective 
of whether patients presented with baseline granulocyte 
counts less than 0.1 X 10y/L or between 0.1 and 0.5 X 
10y/L. However, the enhancing effect of GM-CSF on 
neutrophil recovery did not occur immediately, but was 
only observed 4 to 5 days after the start of treatment.
Despite the faster neutrophil recovery in the GM-CSF 
group, no difference was observed in the resolution of 
fever between the GM-CSF and placebo groups. Previous 
studies demonstrated a distinct correlation between reso­
lution of fever and neutrophil recovery.1 However, these 
studies were conducted almost entirely in patients with a
long-lasting neutropenia,,9'20 The observations apply par­
ticularly to patients with acute leukemia who are treated 
with intensive chemotherapy. The present study and other 
studies in cancer patients show that this correlation is less 
prominent for patients treated with less intensive chemo­
therapy regimens. In these patients, the febrile period is 
usually short and depends on the response to antibiotics. 
In the placebo group, the median duration for resolution 
of fever (<  37.5°C) was 3 days, while a granulocyte count 
greater than 1 X  109/L was reached after a median o f 4 
days. It is possible in the GM-CSF group that GM-CSF 
administration negatively affected the days for resolution 
o f fever. Phase I to II studies have demonstrated that GM- 
CSF might induce fever. However, this was observed 
especially in patients treated with a higher dose of GM- 
CSF.3,21 A recent study o f G-CSF in febrile neutropenia 
also demonstrated that G-CSF hastens neutrophil recov­
ery, but does not affect duration o f fever.10 Since the 
periods of fever and severe granulocytopenia were not 
reduced by GM-CSF treatment, no difference was ob­
served in the duration o f hospitalization. This lack of 
difference in hospitalization duration between both arms 
indicated that GM-CSF treatment was not cost-effective 
for the total group o f patients with chemotherapy-related 
febrile neutropenia. Treatment costs were significantly 
higher than those in the placebo group, mainly due to the 
costs of GM-CSF. In part, this is caused by the fact that 
GM-CSF is only available in vials o f 300 //g and 400  
/¿g. In this study, GM-CSF was administered at a dose 
o f 5.0 ¿¿g/kg/d, which means that a 65-kg patient received 
325 fig of GM-CSF. Correcting for this loss o f GM-CSF 
or applying a 300-¡ig vial only would reduce the costs of 
GM-CSF by approximately 10%.
Adverse events were frequently noted in this study and 
can be ascribed to the underlying disorder and treatment. 
Quality-of-life analyses demonstrated significant differences 
in favor of the placebo group. However, no increased mor­
tality was observed in the GM-CSF-treated group. Different 
cytokines were measured to analyze whether GM-CSF ap-
Table 6. Adverse Events Reported During Treatment With Antibiotics
Plus GM-CSF or Placebo
Adverse Event GM-CSF {%) Placebo (%)
Gastrointestinal 35 23
Cardiac dysfunction 6 1
Biochemical abnormalities 30 27
Thrombosis 3 0
Myalgia 4 1
Rash 4 0
Bone pain 1 1
Edema 12 5
Death 1 2
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Table 7. Cytokine Profiles on Days 0 and 1 of Treatment
Treatment Arm
GM-CSF Placebo
Day 0 Day 1 Day 0 Day 1
GM-CSF (pg/mL) 28 ± 20 709 ± 126* 13.8 ±  3.9 54 ±  37
G-CSF (pg/mL) 3,459 ± 583 2,858 ± 604 2,897 ± 498 2,394 ± 5 1 2
TNF-a (ng/mL) 1.0 ±  0.43 0.18 ±  0.77 2.0 ±  1.2 1.25 ±  0.9
IL-Ó (pg/mL) 304 ±  67 238 ±  57 324 ±  64 262 ±  61
NOTE. Values are the mean ± SE.
‘ Significant difference observed on day 1 of treatment (P <  .0001).
plication might change IL-6, G-CSF, and TNF-a: serum 
levels during treatment. Elevated levels were measured, but 
GM-CSF did not modulate these cytokine profiles signifi­
cantly. Recent studies in mice with non compromised bone 
/narrow have demonstrated that GM-CSF priming is associ­
ated with an enhanced production of cytokines after chal­
lenge with endotoxin and results in increased mortality.23 
However, the present study showed no major changes in 
the cytokine profile during administration of GM-CSF.
Four studies have been conducted in patients with febrile 
neutropenia.8'11 In three studies,9'11 a significant advantage 
was observed for GM-CSF or G-CSF treatment. In the 
present study, only a trend toward an advantage for GM- 
CSF application was seen. The difference might be ascribed 
to differences in patients categories and treatment protocols. 
This is supported by the multivariate analysis in which 
tumor type was an independent prognostic factor for the 
success rate of treatment. Furthermore, a remarkable differ­
ence is observed in the duration of antibiotic application 
between studies, which seems to be a relevant factor for 
the hospitalization period. In the study reported by Riikonen 
et al,9 antibiotic treatment was continued for a minimum 
of 5 days, while in the study reported by Maher et al,10 
antibiotic treatment was continued 4 days after normaliza­
tion of temperature. In the present study, antibiotic treat­
ment was intended to stop after 2 consecutive days with 
resolution of fever and granulocytopenia. The differences in 
antibiotic policy have a great impact on the hospitalization 
period. The median hospitalization days for the GM-CSF 
and G-CSF arm of the studies by Riikonen et al and Maher,
were 9 and 8, respectively. In the present study, the median 
hospitalization duration while on study was 6 days in the 
GM-CSF arm and 7 days in the placebo arm.
The results of this study do not exclude that a subgroup 
of patients, eg, those with a hospitalization period longer 
than 10 days and neutropenia, might benefit from the appli­
cation of GM-CSF. In both previous studies9,10 of febrile 
neutropenia, a significant advantage of hematopoietic 
growth factor application was observed that resulted in a 
significant reduction in hospitalization duration. However, 
in the present study, the follow-up period was only 14 days 
and prolonged hospitalization was only observed in 10% 
of patients, which makes further analyses inadequate. Fi­
nally, the dose of GM-CSF used in this study seems to be 
adequate. A distinct effect was observed on the neutrophil 
recovery. Moreover, the results obtained for duration of 
severe neutropenia were comparable with the G-CSF study, 
in which a dose of 12 /ig/kg/d was used,10
In conclusion, the study presented here demonstrates 
that the application of GM-CSF in febrile neutropenia did 
not result in a significant shortening of the hospitalization 
period, despite a faster recovery of neutrophils for the 
whole group of patients.
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